Overview

Ivermectin for Post Exposure Prophylaxis of Covid-19

Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
Post exposure prophylaxis of healthy contacts is among the measures used for outbreak control of several infectious diseases (e.g., pandemic influenza). No agent is known to be effective in preventing COVID-19, but Ivermectin is one of the drugs that have shown antiviral activity against SARS-CoV-2 in the laboratory. This study aims to evaluate the effect of post exposure prophylaxis with Ivermectin after exposure to COVID-19 among the asymptomatic close contacts.
Phase:
Phase 3
Details
Lead Sponsor:
Clinical Research Centre, Malaysia
Collaborator:
Hovid Berhad
Treatments:
Ivermectin